(NASDAQ: ABUS) Arbutus Biopharma's forecast annual revenue growth rate of -15.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Arbutus Biopharma's revenue in 2024 is $18,141,000.On average, 3 Wall Street analysts forecast ABUS's revenue for 2024 to be $1,996,491,729, with the lowest ABUS revenue forecast at $1,543,632,911, and the highest ABUS revenue forecast at $2,782,129,085. On average, 2 Wall Street analysts forecast ABUS's revenue for 2025 to be $1,748,254,018, with the lowest ABUS revenue forecast at $1,543,632,911, and the highest ABUS revenue forecast at $1,952,875,125.
In 2026, ABUS is forecast to generate $2,159,291,154 in revenue, with the lowest revenue forecast at $2,159,291,154 and the highest revenue forecast at $2,159,291,154.